Which has better earnings and valuation, KZIA or MPLT?

Novogen has higher revenue and earnings than Maplight Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novogen $42K 2,964.34 -$13.41M N/A N/A Maplight Therapeutics N/A N/A -$161.15M -$42.31 N/A

Is KZIA or MPLT more profitable?

Novogen's return on equity of 0.00% beat Maplight Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Novogen N/A N/A N/A Maplight Therapeutics N/A -98.60% -60.33%

Does the media prefer KZIA or MPLT?

In the previous week, Novogen and Novogen both had 3 articles in the media. Maplight Therapeutics' average media sentiment score of 0.34 beat Novogen's score of 0.34 indicating that Maplight Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novogen 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Maplight Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, KZIA or PROK?

Novogen has higher earnings, but lower revenue than ProKidney. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novogen $42K 2,964.34 -$13.41M N/A N/A ProKidney $890K 560.48 -$68.99M -$0.55 N/A

Is KZIA or PROK more profitable?

Novogen has a net margin of 0.00% compared to ProKidney's net margin of -10,288.39%. Company Net Margins Return on Equity Return on Assets Novogen N/A N/A N/A ProKidney -10,288.39% N/A -27.39%

Does the media prefer KZIA or PROK?

In the previous week, Novogen had 1 more articles in the media than ProKidney. MarketBeat recorded 3 mentions for Novogen and 2 mentions for ProKidney. Novogen's average media sentiment score of 0.34 equaled ProKidney'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novogen 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral ProKidney 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, ARVN or KZIA?

Novogen has lower revenue, but higher earnings than Arvinas. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Arvinas $316.70M 1.60 -$80.80M $0.10 78.30 Novogen $42K 2,964.34 -$13.41M N/A N/A

Is ARVN or KZIA more profitable?

Arvinas has a net margin of 2.94% compared to Novogen's net margin of 0.00%. Arvinas' return on equity of 1.91% beat Novogen's return on equity. Company Net Margins Return on Equity Return on Assets Arvinas 2.94% 1.91% 1.29% Novogen N/A N/A N/A

Does the media favor ARVN or KZIA?

In the previous week, Novogen had 2 more articles in the media than Arvinas. MarketBeat recorded 3 mentions for Novogen and 1 mentions for Arvinas. Arvinas' average media sentiment score of 0.59 beat Novogen's score of 0.34 indicating that Arvinas is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arvinas 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Novogen 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer AVTE or KZIA?

Novogen has a consensus price target of $27.33, indicating a potential upside of 184.72%. Given Novogen's stronger consensus rating and higher possible upside, analysts clearly believe Novogen is more favorable than Aerovate Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Novogen 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71

Which has higher valuation and earnings, AVTE or KZIA?

Novogen has higher revenue and earnings than Aerovate Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aerovate Therapeutics N/A N/A -$75.52M -$1.70 N/A Novogen $42K 2,964.34 -$13.41M N/A N/A

Is AVTE or KZIA more profitable?

Novogen's return on equity of 0.00% beat Aerovate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aerovate Therapeutics N/A -90.19% -77.47% Novogen N/A N/A N/A

Which has preferable earnings and valuation, EPRX or KZIA?

Novogen has higher revenue and earnings than Eupraxia Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eupraxia Pharmaceuticals N/A N/A -$38.58M -$1.02 N/A Novogen $42K 2,964.34 -$13.41M N/A N/A

Is EPRX or KZIA more profitable?

Novogen's return on equity of 0.00% beat Eupraxia Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Eupraxia Pharmaceuticals N/A -63.97% -43.32% Novogen N/A N/A N/A

Does the media favor EPRX or KZIA?

In the previous week, Novogen had 1 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 3 mentions for Novogen and 2 mentions for Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals' average media sentiment score of 0.51 beat Novogen's score of 0.34 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eupraxia Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Novogen 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Novogen (KZIA) Competitors

$9.60 -1.32 (-12.09%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$9.90 +0.30 (+3.13%)

As of 09/23/2026 07:30 PM Eastern

Compare

KZIA vs. MPLT, PROK, ARVN, AVTE, and EPRX

Should you buy Novogen stock or one of its competitors? Novogen's main competitors and comparable companies include Maplight Therapeutics (MPLT), ProKidney (PROK), Arvinas (ARVN), Aerovate Therapeutics (AVTE), and Eupraxia Pharmaceuticals (EPRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Novogen compare to Maplight Therapeutics?

Novogen (NASDAQ:KZIA) and Maplight Therapeutics (NASDAQ:MPLT) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership.

Novogen currently has a consensus price target of $27.33, suggesting a potential upside of 184.72%. Maplight Therapeutics has a consensus price target of $29.50, suggesting a potential upside of 173.91%. Given Novogen's higher probable upside, research analysts plainly believe Novogen is more favorable than Maplight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novogen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Maplight Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	4 Strong Buy rating(s)	2.94

In the previous week, Novogen and Novogen both had 3 articles in the media. Maplight Therapeutics' average media sentiment score of 0.34 beat Novogen's score of 0.34 indicating that Maplight Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novogen	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Maplight Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Novogen has higher revenue and earnings than Maplight Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novogen	$42K	2,964.34	-$13.41M	N/A	N/A
Maplight Therapeutics	N/A	N/A	-$161.15M	-$42.31	N/A

30.9% of Novogen shares are held by institutional investors. 1.0% of Novogen shares are held by insiders. Comparatively, 3.8% of Maplight Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Novogen's return on equity of 0.00% beat Maplight Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novogen	N/A	N/A	N/A
Maplight Therapeutics	N/A	-98.60%	-60.33%

Summary

Novogen beats Maplight Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Novogen compare to ProKidney?

Novogen (NASDAQ:KZIA) and ProKidney (NASDAQ:PROK) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings.

In the previous week, Novogen had 1 more articles in the media than ProKidney. MarketBeat recorded 3 mentions for Novogen and 2 mentions for ProKidney. Novogen's average media sentiment score of 0.34 equaled ProKidney'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novogen	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
ProKidney	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Novogen has a net margin of 0.00% compared to ProKidney's net margin of -10,288.39%.

Company	Net Margins	Return on Equity	Return on Assets
Novogen	N/A	N/A	N/A
ProKidney	-10,288.39%	N/A	-27.39%

Novogen presently has a consensus target price of $27.33, suggesting a potential upside of 184.72%. ProKidney has a consensus target price of $12.00, suggesting a potential upside of 627.27%. Given ProKidney's higher probable upside, analysts plainly believe ProKidney is more favorable than Novogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novogen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
ProKidney	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Novogen has higher earnings, but lower revenue than ProKidney.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novogen	$42K	2,964.34	-$13.41M	N/A	N/A
ProKidney	$890K	560.48	-$68.99M	-$0.55	N/A

Novogen has a beta of 2.14, suggesting that its stock price is 114% more volatile than the broader market. Comparatively, ProKidney has a beta of 1.7, suggesting that its stock price is 70% more volatile than the broader market.

30.9% of Novogen shares are held by institutional investors. Comparatively, 51.6% of ProKidney shares are held by institutional investors. 1.0% of Novogen shares are held by company insiders. Comparatively, 39.8% of ProKidney shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Novogen beats ProKidney on 8 of the 13 factors compared between the two stocks.

How does Novogen compare to Arvinas?

Arvinas (NASDAQ:ARVN) and Novogen (NASDAQ:KZIA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, media sentiment and valuation.

Novogen has lower revenue, but higher earnings than Arvinas.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arvinas	$316.70M	1.60	-$80.80M	$0.10	78.30
Novogen	$42K	2,964.34	-$13.41M	N/A	N/A

Arvinas has a beta of 1.75, indicating that its stock price is 75% more volatile than the broader market. Comparatively, Novogen has a beta of 2.14, indicating that its stock price is 114% more volatile than the broader market.

95.2% of Arvinas shares are held by institutional investors. Comparatively, 30.9% of Novogen shares are held by institutional investors. 7.3% of Arvinas shares are held by company insiders. Comparatively, 1.0% of Novogen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Novogen had 2 more articles in the media than Arvinas. MarketBeat recorded 3 mentions for Novogen and 1 mentions for Arvinas. Arvinas' average media sentiment score of 0.59 beat Novogen's score of 0.34 indicating that Arvinas is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arvinas	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Novogen	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Arvinas has a net margin of 2.94% compared to Novogen's net margin of 0.00%. Arvinas' return on equity of 1.91% beat Novogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arvinas	2.94%	1.91%	1.29%
Novogen	N/A	N/A	N/A

Arvinas currently has a consensus price target of $14.55, suggesting a potential upside of 85.77%. Novogen has a consensus price target of $27.33, suggesting a potential upside of 184.72%. Given Novogen's stronger consensus rating and higher possible upside, analysts clearly believe Novogen is more favorable than Arvinas.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arvinas	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.30
Novogen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

Arvinas and Novogen tied by winning 7 of the 14 factors compared between the two stocks.

How does Novogen compare to Aerovate Therapeutics?

Aerovate Therapeutics (NASDAQ:AVTE) and Novogen (NASDAQ:KZIA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations, dividends and media sentiment.

Aerovate Therapeutics has a beta of 0.95, indicating that its share price is 5% less volatile than the broader market. Comparatively, Novogen has a beta of 2.14, indicating that its share price is 114% more volatile than the broader market.

30.9% of Novogen shares are owned by institutional investors. 24.9% of Aerovate Therapeutics shares are owned by company insiders. Comparatively, 1.0% of Novogen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Novogen has higher revenue and earnings than Aerovate Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A
Novogen	$42K	2,964.34	-$13.41M	N/A	N/A

Novogen has a consensus price target of $27.33, indicating a potential upside of 184.72%. Given Novogen's stronger consensus rating and higher possible upside, analysts clearly believe Novogen is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Novogen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, Novogen had 3 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 3 mentions for Novogen and 0 mentions for Aerovate Therapeutics. Novogen's average media sentiment score of 0.34 beat Aerovate Therapeutics' score of 0.00 indicating that Novogen is being referred to more favorably in the news media.

Company	Overall Sentiment
Aerovate Therapeutics	Neutral
Novogen	Neutral

Novogen's return on equity of 0.00% beat Aerovate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aerovate Therapeutics	N/A	-90.19%	-77.47%
Novogen	N/A	N/A	N/A

Summary

Novogen beats Aerovate Therapeutics on 11 of the 12 factors compared between the two stocks.

How does Novogen compare to Eupraxia Pharmaceuticals?

Eupraxia Pharmaceuticals (NASDAQ:EPRX) and Novogen (NASDAQ:KZIA) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends, media sentiment and profitability.

Novogen's return on equity of 0.00% beat Eupraxia Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eupraxia Pharmaceuticals	N/A	-63.97%	-43.32%
Novogen	N/A	N/A	N/A

Novogen has higher revenue and earnings than Eupraxia Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58M	-$1.02	N/A
Novogen	$42K	2,964.34	-$13.41M	N/A	N/A

30.9% of Novogen shares are held by institutional investors. 1.0% of Novogen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Eupraxia Pharmaceuticals currently has a consensus target price of $18.00, suggesting a potential upside of 121.13%. Novogen has a consensus target price of $27.33, suggesting a potential upside of 184.72%. Given Novogen's higher probable upside, analysts plainly believe Novogen is more favorable than Eupraxia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eupraxia Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
Novogen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Eupraxia Pharmaceuticals has a beta of 1.07, suggesting that its share price is 7% more volatile than the broader market. Comparatively, Novogen has a beta of 2.14, suggesting that its share price is 114% more volatile than the broader market.

In the previous week, Novogen had 1 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 3 mentions for Novogen and 2 mentions for Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals' average media sentiment score of 0.51 beat Novogen's score of 0.34 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eupraxia Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Novogen	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Novogen beats Eupraxia Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

Get Novogen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KZIA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KZIA vs. The Competition

Export

Metric	Novogen	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$141.62M	$3.98B	$7.31B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	N/A	13.88	274.08	25.69
Price / Sales	2,964.34	1,343.77	638.21	78.99
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	-1.80	15.40	10.47	6.32
Net Income	-$13.41M	-$22.82M	$3.49B	$359.73M
7 Day Performance	-11.60%	-1.70%	-0.67%	0.17%
1 Month Performance	-27.27%	-6.17%	-3.17%	-3.27%
1 Year Performance	21.83%	30.67%	15.14%	5.58%

Novogen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KZIA Novogen	3.5415 of 5 stars	$9.60 -12.1%	$27.33 +184.7%	+26.6%	$141.62M	$42K	N/A	6
MPLT Maplight Therapeutics	2.807 of 5 stars	$11.86 -1.8%	$29.50 +148.8%	N/A	$550.28M	N/A	N/A	133
PROK ProKidney	1.7843 of 5 stars	$1.80 +3.2%	$12.00 +568.5%	-39.8%	$542.66M	$890K	N/A	231	Gap Up
ARVN Arvinas	2.9668 of 5 stars	$8.19 -0.9%	$14.17 +73.1%	+4.0%	$530.03M	$262.60M	82.16	246
AVTE Aerovate Therapeutics	N/A	$18.18 +1.6%	N/A	+111.6%	$526.95M	N/A	N/A	20	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KZIA) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Novogen (KZIA) Competitors

KZIA vs. MPLT, PROK, ARVN, AVTE, and EPRX

How does Novogen compare to Maplight Therapeutics?

Summary

How does Novogen compare to ProKidney?

Summary

How does Novogen compare to Arvinas?

Summary

How does Novogen compare to Aerovate Therapeutics?

Summary

How does Novogen compare to Eupraxia Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KZIA vs. The Competition

Novogen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Novogen (KZIA) Competitors

KZIA vs. MPLT, PROK, ARVN, AVTE, and EPRX

How does Novogen compare to Maplight Therapeutics?

Do analysts rate KZIA or MPLT?

Does the media prefer KZIA or MPLT?

Which has better earnings and valuation, KZIA or MPLT?

Do insiders & institutionals have more ownership in KZIA or MPLT?

Is KZIA or MPLT more profitable?

Summary

How does Novogen compare to ProKidney?

Does the media prefer KZIA or PROK?

Is KZIA or PROK more profitable?

Do analysts rate KZIA or PROK?

Which has higher earnings and valuation, KZIA or PROK?

Which has more risk & volatility, KZIA or PROK?

Do insiders & institutionals hold more shares of KZIA or PROK?

Summary

How does Novogen compare to Arvinas?

Which has better earnings & valuation, ARVN or KZIA?

Which has more risk & volatility, ARVN or KZIA?

Do insiders and institutionals have more ownership in ARVN or KZIA?

Does the media favor ARVN or KZIA?

Is ARVN or KZIA more profitable?

Do analysts prefer ARVN or KZIA?

Summary

How does Novogen compare to Aerovate Therapeutics?

Which has more risk and volatility, AVTE or KZIA?

Do institutionals and insiders believe in AVTE or KZIA?

Which has higher valuation and earnings, AVTE or KZIA?

Do analysts prefer AVTE or KZIA?

Does the media favor AVTE or KZIA?

Is AVTE or KZIA more profitable?

Summary

How does Novogen compare to Eupraxia Pharmaceuticals?

Is EPRX or KZIA more profitable?

Which has preferable earnings and valuation, EPRX or KZIA?

Do insiders and institutionals have more ownership in EPRX or KZIA?

Do analysts prefer EPRX or KZIA?

Which has more volatility and risk, EPRX or KZIA?

Does the media favor EPRX or KZIA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KZIA vs. The Competition

Novogen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools